Volume 2, Issue1, January 2011

Available Online at www.ijppronline.com

International Journal Of Pharma Professionals Research

Review Article

DISSOLUTION:- Life line of Pharmaceutics

Shekhar Singh*1,Shaweta Sharma1, Abdul Hafeez1

ISSN NO:0976-6723

1)Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, U.P. India

Abstract
In this present review we studied the different dissolution parameters which are required for the dissolution. Different types of dissolution apparatus in detail with the help of diagram to understand it well. The validation procedures for the dissolution apparatus and its devices. we also study the different types of buffers which are used in dissolution their preparation methods are also included in it. From this study we concluded that anyone can go familiar with the dissolution, its apparatus and the buffers . Keywords: - Dissolution, Dissolution Apparatus, Validation, Buffers. USP and FDA Requirements for Basket Apparatus Introduction Dissolution testing is a requirement for all solid oral The basket apparatus consists of a wire-mesh basket that is dosage forms and is used for drug product release and attached to a rotation shaft, which is then immersed into a stability testing. The dissolution test is the most dissolution vessel for the duration of the dissolution test. Since the important analytical test for detecting physical changes dosage unit is in direct contact with the basket, the physical in an API and in the formulation. The two commonly dimensions and motion of the basket can have a dramatic effect on used dissolution apparatus are the basket (USP the dissolution rate of the solid dosage unit. Because of the critical nature of the basket, it is tightly controlled by several mechanisms. Apparatus 1) and the paddle (USP Apparatus 2). Both apparatus have been widely accepted by the First, the dimensions of basket height, i.d. and o.d. of the basket pharmaceutical community for measuring the rate of opening, height of the open screen, and size of the mesh are dissolution of an API from a given pharmaceutical solid specified in USP <711>. Next, the amount of wobble at the dosage form. The setup of dissolution Apparatus 1 and 2 bottom of the basket while rotating is checked with a wobble requires control over many variables as defined in USP meter at periodic intervals, anywhere from time of use to once a <711> (1), European Pharmacopoeia 2.9.3 (2), and year, to ensure that it is within the 1-mm specification indicated in Japanese Pharmacopoeia 15 (3). The variables in both of USP.Finally, a functional test using standardized performancethese apparatus are vessels, shaft dimensions, shaft verification tablets is executed. The rate of release of the wobble, rotation speed, shaft height from the bottom of standardized calibrator tablet is measured and compared to the the vessel, vessel centering and tilt, temperature, acceptance criteria. The performance verification tablets and leveling of the dissolution apparatus at its base, acceptance criteria are designed so that if the apparatus is not set vibration, and so forth. Many literature articles describe up in accordance with the tight USP specifications, it will not pass methods to control these variables (420). However, this final test.(21-23) none of these address control of basket variability (refer Dissolution Test This test is designed to determine compliance with the dissolution to USP <711>). requirements for solid dosage forms administered orally. The test Correspondence Address: is intended for a capsule or tablet. Use Apparatus 1 unless Shekhar Singh otherwise directed. All parts of the apparatus that may come into Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, U.P. contact with the preparation under examination or with the dissolution medium are chemically inert and do not adsorb, react India- 244001. or interfere with the preparation under examination. All metal Email: [email protected] parts of the apparatus that may come into contact with the Phone:91-9368902763 preparation or the dissolution medium must be made from 224

Volume 2, Issue1, January 2011 stainless steel, type 316 or equivalent or coated with a suitable material to ensure that such parts do not react or interfere with the preparation under examination or the dissolution medium. No part of the assembly, including the environment in which the assembly is placed, contributes significant motion, agitation or vibration beyond that due to the smoothly rotating element. An apparatus that permits observation of the preparation under examination and the stirrer during the test is preferable.

An assembly consisting of the following: a. A cylindrical vessel, A, made of borosilicate glass or any other suitable transparent material, with a hemispherical bottom and with a nominal capacity of 1000ml and an inside diameter of 98-106 mm . The vessel has a flanged upper rim and is fitted with a lid that has a number of openings, one of which is central. b. A motor with a speed regulator capable of maintaining the speed of rotation of the paddle within 4 per cent of that specified in the individual monograph. The motor is fitted with a stirring element which consists of a drive shaft and blade forming a paddle, B. The blade passes through the diameter of the shaft so that the bottom of the blade is flush with the bottom of the shaft. The shaft is positioned so that its axis is within 2 mm of the axis of the vessel and the lower edge of the blade is 23 to 27 mm from the inside bottom of the vessel. The apparatus operates insuch a way that the paddle rotates smoothly and without significant wobble. c. A water-bath set to maintain the dissolution medium at 36.5 to 37.5. The bath liquid is kept in constant and smooth motion during the test. The vessel is securely clamped in the waterbath in such a way that the displacement vibration from other equipment, including the water circulation device, is minimised.

The assembly is the same as in Apparatus 1 except that in the stirring element the paddle is replaced by a basket, D . The metallic shaft rotates smoothly and without significant wobble. The basket consists of two components. The top part, with a vent, is attached to the shaft C, it is fitted with three spring clips, or other suitable means, that allow removal of the lower part for introduction of the preparation under examination and that firmly hold the lower part of the basket concentric with the axis of the vessel during rotation. The lower detachable part of the basket is made of welded-steam cloth, with a wire thickness of 0.254 mm diameter and with 0.381mm square openings, formed into a cylinder with narrow rim of sheet metal around the top and the bottom. The basket may be plated with a 2.5m m layer of gold for use with acidic media. The distance between the inside bottom of the vessel and the basket is maintained at 23 to 27mm during the test.[24] The two components of the dissolution test are simple: sample preparation, which takes place within the dissolution apparatus, and sample analysis, primarily via chromatographic or spectrophotometric techniques. The two components of the dissolution test, sample preparation and assay, are separated by a filtration step. Filters must be validated to prove their efficiency in removing undissolved active pharmaceutical ingredient (API) from the sample and to verify that they do not adsorb dissolved API, which affects the integrity of the sample concentration. The first step taken to overcome concentration and sensitivity issues is usually modification of the analytical method by taking advantage of a larger path length for a spectrophotometer or a larger injection volume for high performance liquid chromatography (HPLC). When success with these techniques is limited, we must focus on the dissolution apparatus where a reduction in media volume may be a more rugged solution.[25] Only a few of the compendial dissolution and drug-release apparatus are designed for low-dose compounds and volume requirements less than 100 mL present additional challenges to the traditional paddle and basket apparatus. Rugged dissolution 225

Volume 2, Issue1, January 2011 methods should quantify the low levels of analyte o Demonstrate a release of 80% or an asymptote. accurately and precisely, especially in the initial stages The method should also be capable of showing discrimination, of drug release in the dissolution profile. Accurate rejecting lots, and ultimately demonstrating consistency of analytical concentration in the presence of reliable and performance from lot to lot. In terms of dissolution specifications consistent agitation is the primary requirement of any for modified release products, expectations are high for in vitroin dissolution test but demands extreme precision in low- vivo correlation (IVIVC), and the small-volume dissolution volume conditions to ensure data accuracy. The apparatus should provide data needed to support scale-up and dissolution apparatus must operate under conditions of post-approval changes for modified-release (SUPAC-MR) (29). controlled temperature, agitation rate, precise Additionally, the dissolution test should be approvable based on hydrodynamics, and volume. To maintain precise meaningful methodology and specifications, and in general, the hydrodynamics, the apparatus must maintain overall method must be relevant, predictable, specific, and discernable physical uniformity and alignment throughout the test. (30). Standard dissolution apparatus may be obtained from Dissolution medium. Use the dissolution medium specified in the manufactures that produce the equipment according to individual monograph. If the medium is a buffered solution, adjust the specification and tolerances outlined in General Test the solution so that its pH is within 0.05 units of the pH specified Chapter <711> Dissolution (26). For low concentrations in the monograph. The dissolution medium should be deaerated of API, official compendia apparatus may be incapable prior to testing. [31] of maintaining quantitative levels of analyte during the Method dissolution of oral dosage units containing microgram or Conventional and prolonged-release solid dosage forms nanogram levels. Dissolution of typical high-potency, Place the stated volume of the dissolution medium, free from low-dose compounds may require a reduction in vessel dissolved air, into the vessel of the apparatus. Assemble the volume accompanied by an alteration in apparatus apparatus and warm the dissolution medium to 36.5 to 37.5. design due to limitations in detection and quantitation. If Unless otherwise stated, place one dosage unit in the apparatus, a reduction in volume is considered and the apparatus is taking care to exclude air bubbles from the surface of the dosage modified, the operating conditions of the modified unit. When Apparatus 1 is used, allow the tablet or capsule to sink apparatus should maintain the same degree of precision to the bottom of the vessel prior to the rotation of the paddle. A and alignment required for any other compendial suitable device such as a wire of glass helix may be used to keep dissolution apparatus. Small-volume apparatus are horizontal at the bottom of the vessel tablets or capsules that desired not only for high-potency, low-dose would otherwise float. formulations. Small-volume dissolution utilizing a mini When Apparatus 2 is used, place the tablet or capsule in a dry paddle has been suggested as an alternative to standard basket at the beginning of each test. Lower the basket into position paddle methods that require large volumes of before rotation. Operate the apparatus immediately at the speed of biorelevant medium. This can be very expensive, and rotation specified in the individual monograph. Within the time there may be limitations of large sample size or active interval specified, or at each of the times stated, withdraw a drug availability in the early stages of drug development specimen from a zone midway between the surface of the (27). dissolution medium and the top of the rotating blade or basket, not In the current regulatory environment, our dissolution less than 10 mm from the wall of the vessel. Except in the case of methods must be accurate, sensitive, and specific, and single sampling, add a volume of dissolution medium equal to the the reproducibility of the test method employed must be volume of the samples withdrawn. Perform the analysis as established, verified, and documented (28). directed in the individual monograph. Repeat the whole operation Additionally, the method must maintain limits of five times. Where two or more tablets or capsules are directed to detection and quantitation, range, and linearity and be placed together in the apparatus, carry out six replicate tests. discriminate variation from batch to batch. Small- For each of the tablet or capsule tested, calculate the amount of volume apparatus components should be precisely dissolved active ingredient in solution as a percentage of the stated designed, rugged, and commercially available to aid in amount where two or more tablets or capsules are placed together, the approval of the noncompendial method and determine for each test the amount of active ingredient in solution analytical transferability. Regulatory expectations of the per tablet or capsules and calculate as a percentage of the stated small-volume dissolution method should continue to: amount. o Characterize the in vitro release early in Acceptance criteria development. Conventional-release dosage forms o Evaluate release with various conditions of Unless otherwise specified, the requirements are met if the agitation, media composition, pH, and temperature. quantities of active substance dissolved from the dosage units o Establish optimum test conditions. conform to Table If the results do not conform to the requirements 226

Volume 2, Issue1, January 2011 at stage S1 given in the table, continue testing with dosage units conform to Table. If the results do not conform to the additional dosage units through stages S2 and S3 unless requirements at stage L1 given in the table, continue testing with the results conform at stage S2. Where capsule shells additional dosage units through stages L2 and L3 unless the results interfere with the analysis, remove the contents of not conform at stage L2. The limits embrace each value of D, the less than 6 capsules as completely as possible, and amount dissolved at each specified dosing interval. Where more dissolve the empty capsule shells in the specified than one range is specified, the acceptance criteria apply to each volume of the dissolution medium. Perform the analysis range. as directed in the individual monograph. Make any Modified-release dosage forms. Use method A or Method B. necessary correction. Correction factors should not be MethodA greater than 25 per cent of the stated amount Acid stage. Place 750 ml of 0.1M hydrochloric acid in the vessel, and assemble the apparatus. Warm the dissolution medium to Lev Number Acceptance criteria 36.5 to 37.5. Place one dosage unit in the apparatus, cover the el Tested Each unit is not less than D* + 5 vessel and operate the apparatus at the specified rate. After 2 hours S1 6 percent**. of operation in the acid medium, withdraw an aliquot of the liquid Average of 12 units (S1 +S2) is S2 6 and proceed immediately as directed under Buffer stage. Perform equal to or greater than D, and no the analysis of the aliquot using a suitable assay method. unit is less than D 15 per Buffer stage. Complete the operations of adding the buffer and cent**. adjusting the pH within 5 minutes. With the apparatus operating at Average of 24 units S3 12 the rate specified, add to the medium in the vessel 250 ml of a 0.2 (S1+S2+S3)is equal to or greater M solution of trisodium phosphate dodecahydrate that has been than D, not, More than 2 units are warmed to 36.5 to 37.5. Adjust, if necessary, with 2M less than D 15 per cent** and hydrochloric acid or 2M sodium hydroxide to a pH of 6.8 0.05. no unit is less than D 25 per 2M hydrochloric acid or 2M sodium hydroxide to a pH of 6.8 cent**. *D is the amount of dissolved active ingredient specified 0.05. in the individual monograph, expressed as a percentage Method B Acid stage. Place 1000 ml of 0.1M hydrochloric acid in the vessel of the labelled content. and assemble the apparatus. Warm the dissolution medium to **Percentages of the labelled content. 36.5 to 37.5. Place one dosage unit in the apparatus, cover the vessel and operate the apparatus at the specified rate. After 2 hours of operation in the acid medium, withdraw an aliquot of the liquid and proceed immediately as directed under Buffer stage. Perform the analysis of the aliquot using a suitable assay method. Buffer stage. Use buffer that has previously been warmed to 36.5 to 37.5. Drain the acid from the vessel and add 1000 ml of pH 6.8 phosphate buffer, prepared by mixing 3 volumes of 0.1M hydrochloric acid with 1 volume of 0.2 M solution of trisodium phosphate dodecahydrate and adjusting, if necessary, with 2M hydrochloric acid or 2M sodium hydroxide to a pH of 6.8 0.05. This may also be done by removing from the apparatus the vessel containing the acid and replacing it with another vessel containing the buffer and transferring the dosage unit to the vessel containing the buffer. Continue to operate the apparatus for 45 minutes, or for the specified time. At the end of this period, withdraw an aliquot of the liquid and perform the analysis using a suitable assay method.[32] Acceptance criteria Acid stage. Unless otherwise specified, the requirements of this part of the test are met if the quantities, based on the percentage of the labelled content of active substance dissolved from the units tested conform to Table . Continue the testing through the 3 levels Prolonged-release dosage forms Unless otherwise specified, the requirements are met if unless the results of both acid and buffer stages conform at an earlier level. the quantities of active substance dissolved from the 227

Volume 2, Issue1, January 2011 the apparatus, taking care to exclude air bubbles from the surface Acceptance criteria No individual value of the dosage-form unit, and immediately operate the apparatus at exceeds 10 percent the rate specified in the individual monograph. Within the time interval specified, or at each of the times stated, withdraw a dissolved. The average value of the specimen from a zone midway between the surface of the A2 6 12 units (A1 + A2) is not Dissolution Medium and the top of the rotating basket or blade, more than 10 per cent not less than 1 cm from the vessel wall. [NOTEReplace the dissolved, and no aliquots withdrawn for analysis with equal volumes of fresh individual unit is greater Dissolution Medium at 378 or, where it can be shown that than 25 per cent replacement of the medium is not necessary, correct for the volume change in the calculation. Keep the vessel covered for the dissolved. The average value of the duration of the test, and verify the temperature of the mixture A3 12 24 units (A1 + A2 + A3) under test at suitable times.] Perform the analysis as directed in the is not more than 10 per individual monograph. Repeat the test with additional dosage form cent dissolved, and no units. If automated equipment is used for sampling and the individual unit is greater apparatus is modified, validation of the modified apparatus is than 25 per cent needed to show that there is no change in the agitation characteristics of the test. dissolved. Buffer stage. Unless otherwise specified, the Where capsule shells interfere with the analysis, remove the requirements of this part of the test are met if the contents of not fewer than 6 capsules as completely as possible, quantities, based on the percentage of the labelled and dissolve the empty capsule shells in the specified volume of content of active substance dissolved from the units Dissolution Medium. Perform the analysis as directed in the tested conform to Table . Continue the testing through individual monograph. Make any necessary correction. Correction the 3 levels unless the results of both acid and buffer factors greater than 25% of the labeled content are unacceptable. stages conform at an earlier level. The value of D in Procedure for a Pooled Sample for Capsules, Uncoated Table is 75 per cent dissolved unless otherwise Tablets, and Plain Coated Tablets Use this procedure where specified. The quantity, D, is the specified total amount Procedure for a Pooled Sample is specified in the individual of active substance dissolved in both the acid and buffer monograph. Proceed as directed under Procedure for Capsules, stages, expressed as a percentage of the labelled Uncoated Tablets, and Plain Coated Tablets. Combine equal volumes of the filtered solutions of the six or twelve individual content.[33] specimens withdrawn, and use the pooled sample as the test Level Number Tested Acceptance criteria No unit is less than D + 5 solution. Determine the average amount of the active ingredient B1 6 dissolved in the pooled sample. per cent* The average value of the Dissolution Medium B2 6 12 units (B1+ B2) is Dissolution testing should be carried out under physiological equal to or greater than conditions, if possible. This allows interpretation of dissolution D,and no unit is less than data with regard to in vivo performance of the product. However, bstrict adherence to the gastrointestinal environment need not be D 15 per cent* The average value of 24 used in routine dissolution testing. The testing conditions should B3 12 units (B1 + B2 + B3) is be based on physicochemical characteristics of the drug substance equal to or greater than and the environmental conditions the dosage form might be D, not more than 2 units exposed to after oral administration. are less than D 15 per The volume of the dissolution medium is generally 500, 900, or cent*, and no unit is less 1000 mL. Sink conditions are desirable but not mandatory. An aqueous medium with pH range than D 25 per cent*. 1.2 to 6.8 (ionic strength of * percentages of the labelled content. Procedure for Capsules, Uncoated Tablets, and Plain buffers the same as in USP) should be used. To simulate intestinal fluid (SIF), a dissolution medium of pH 6.8 should be employed. Coated Tablets Place the stated volume of the Dissolution Medium A higher pH should be justified on a case-by-case basis and, in (+1%) in the vessel of the apparatus specified in the general, should not exceed pH 8.0. To simulate gastric fluid individual monograph, assemble the apparatus, (SGF), a dissolution medium of pH 1.2 should be employed equilibrate the Dissolution Medium to 37+0.58, and without enzymes. The need for enzymes in SGF and SIF should be evaluated on a case-by-case basis and should be justified. Recent remove the thermometer. Place 1 tablet or 1 capsule in Level A1 Number Tested 6 228

Volume 2, Issue1, January 2011 experience with gelatin capsule products indicates the have been used for various purposes such as the dissolution of possible need for enzymes (pepsin with SGF and esomeprazole magnesium and omeprazole magnesium, which are pancreatin with SIF) to dissolve pellicles, if formed, to carried out in the acid stage using only 300 mL of 0.1 M HCl ( 8), permit the dissolution of the drug. Use of water as a in general, the hydrodynamics below 500 mL become too unstable dissolution medium also is discouraged because test for routine dissolution testing. The traditional vessel has handled conditions such as pH and surface tension can vary routine oral dosage tablets, capsules, suspensions, suppositories, depending on the source of water and may change and chewable tablets, but smaller-volume vessels with scaledduring the dissolution test itself, due to the influence of down basket and paddles (Figure 1) have been developed to the active and inactive ingredients. For water insoluble handle volumes capable of nano- and picogram levels of drug. The or sparingly water soluble drug products, use of a operational minimum for small-volume vessels of 100 mL and surfactant such as sodium lauryl sulfate is recommended 200 mL is approximately 30 mL. (34,35). The need for and the amount of the surfactant USP Apparatus 1 Rotating Basket should be justified. Use of a hydro alcoholic medium is Apparatus 1The assembly consists of the following: a covered discouraged. vessel made of glass or other inert, transparent material1; a motor;

Discussion of Dissolution Apparatus

Over the years, the traditional paddle and basket dissolution apparatus with 1-L vessels has been an important tool for characterizing the biopharmaceutical quality of a product at different stages in the product life cycle. Our discussion will focus on those official apparatus contained in the current USP (36,37). Apparatus mentioned in the following sections contain recognized minimum operational volumes. Consultation with the manufacturers of these apparatus is recommended to obtain the latest performance specifications if further reductions in vessel volume are desired. Apparatus will be discussed according to their USP apparatus numbers, and additional information will follow each apparatus regarding its noncompendial modifications to achieve small-volume dissolution. USP Dissolution Apparatus Apparatus 1 - Basket (37) Apparatus 2 - Paddle (37) Apparatus 3 - Reciprocating Cylinder (37) Apparatus 4 Flow-Through Cell (37) Apparatus 5 Paddle over Disk (32), Transdermal Delivery System, use paddle and vessel from Apparatus 2 with a stainless steel disk assembly to hold the transdermal on the bottom of vessel. Apparatus 6, Cylinder (32), Transdermal Delivery System, use Apparatus 1 except replace the basket shaft with a stainless steel cylinder element. Apparatus 7, Reciprocating Holder, for transdermal delivery systems and also a variety of dosage forms. USP Apparatus --- Rotating Basket and Paddle The traditional basket and paddle apparatus utilize a 1000-mL hemispheric bottom vessel. To accomplish sink conditions required for bolus and poorly soluble dosage forms, vessels up to 4000 mL have been incorporated into the USP, but the operational minimum of the 1000-mL vessel is around 500 mL. Although smaller volumes 229

Volume 2, Issue1, January 2011 a metallic drive shaft; and a cylindrical basket. The inert coating. The dosage unit is allowed to sink to the bottom of vessel is partially immersed in a suitable water bath of the vessel before rotation of the blade is started. A small, loose any convenient size or placed in a heating jacket. The piece of nonreactive material such as not more than a few turns of water bath or heating jacket permits holding the wire helix may be attached to dosage units that would otherwise temperature inside the vessel at 37+0.58 during the test float. Other validated sinker devices may be used. and keeping the bath fluid in constant, smooth motion. No part of the assembly, including the environment in which the assembly is placed, contributes significant motion, agitation, or vibration beyond that due to the smoothly rotating stirring element. Apparatus that permits observation of the specimen and stirring element during the test is preferable. The vessel is cylindrical, with a hemispherical bottom and with one of the following dimensions and capacities: for a nominal capacity of 1 L, the height is 160 mm to 210 mm and its insidediameter is 98 mm to 106 mm; for a nominal capacity of 2 L, the height is 280mm to 300 mm and its inside diameter is 98 mm to 106 mm; and for a nominal capacity of 4 L, the height is 280 mm to 300 mm and its inside diameter is 145 mm to 155 mm. Its sides are flanged at the top. A fitted cover may be used to retard evaporation. The shaft is positioned so that its axis is not more than 2 mm at any point from the vertical axis of the vessel and rotates smoothly and without significant wobble. A speed-regulating device is used that allows the shaft rotation speed to be selected and maintained at the rate specified in the individual monograph, within +4%.Shaft and basket components of the stirring element are fabricated of stainless steel, type 316 or equivalent, to the specifications shown in Figure 1. Unless otherwise specified in the individual monograph, use 40-mesh cloth. A basket having a gold coating 0.0001 inch (2.5 mm) thick may be used. The dosage unit is placed in a dry basket at the beginning of each test. The distance between the inside bottom of the vessel and the basket is maintained at 25+2 mm during the test. Apparatus 2 paddle type Use the assembly from Apparatus 1, except that a paddle formed from a blade and a shaft is used as the stirring element. The shaft is USP Apparatus 3Reciprocating Cylinder positioned so that its axis is not more than 2 mm at any The reciprocating cylinder apparatus has six or seven inner tubes, point from the vertical axis of the vessel and rotates smoothly without significant wobble. The vertical center which mechanically traverse six rows of corresponding mediafilled outer tubes. Also called the Bio-Dis, for biorelevant line of the blade passes through the axis of the shaft so that the bottom of the blade is flush with the bottom of dissolution, the apparatus has been successfully used for tablets, the shaft. The paddle conforms to the specifications capsules, beads (Figure 2), and other extended-release dosage forms that require exposure to various media representing shown in Figure 2. The distance of 25+2 mm between the blade and the inside bottom of the vessel is conditions in the gastrointestinal tract. The traditional configuration utilizes a 300-mL vessel, which is an advantage for maintained during the test. The metallic or suitably inert, products requiring a small volume. The reciprocating cylinder has rigid blade and shaft comprise a single entity. A suitable two-part detachable design may be used provided the an operational minimum of about 150 mL. A noncompendial version has been developed; it utilizes a 100-mL vessel with a assembly remains firmly engaged during the test. The scaled-down reciprocating inner tube that can run at an operational paddle blade and shaft may be coated with a suitable minimum of about 50 mL 230

Volume 2, Issue1, January 2011 capsules, powders, tablets, implants, and suppositories and has been used with a wide range of media volume. A compendial closed system with a small media reservoir could traditionally reduce volume to less than 100 mL for the official USP 12- and 26-mm cells. Noncompendial cells that allow dissolution of nanoparticles and suppositories have been developed. Smallvolume applications have been refined for the flow-through apparatus, resulting in closed cells handling dissolution volumes less than 15 mL. These smaller cells have been developed for implants and other low-dose products.

USP Apparatus 4Flow-Through Cell The flow-through cell was originally developed to simulate gastrointestinal conditions by exposing extended-release and poorly soluble dosage forms to media of varying pH. The apparatus has been used for 231

Volume 2, Issue1, January 2011 USP Apparatus 5 and 6Paddle Over Disk and typically 30 cycles per minute at an amplitude of 2 cm, but a specific vessel size has not been stated in the USP General Rotating Cylinder These two methods were developed for transdermal Chapter <724> Drug Release (37). The original reciprocating systems, and the official vessel is the traditional 1000- holder apparatus commonly used 50400-mL vessels and was not mL hemispheric bottom dissolution vessel mentioned initially designed for extremely low volumes. The reciprocating previously. The minimum vessel volume is 500 mL due cylinder apparatus has become a good candidate for modification to the hydrodynamic issue mentioned for the paddle due to the emergence of numerous low-dose compounds that have apparatus. No smaller vessels have been developed or challenged traditional dissolution equipment. These dosage forms applied to USP Apparatus 5 or 6 to the authors include subcutaneous implants and combination products such as knowledge at this time. drug-eluting stents (Figure 3). Currently, Apparatus 7 can accommodate a dissolution environment as low as 5 mL.

USP Apparatus 7Reciprocating Holder Originally introduced in the USP as a small-volume option for small transdermal patches, the reciprocating disk apparatus was later renamed the reciprocating holder apparatus with the adoption of four additional holders for transdermal systems, osmotic pumps, and other low-dose delivery systems. The agitation rate for the reciprocating holder apparatus has been

Validation of a Dissolution Apparatus:Dissolution is defined as the process by which a known amount of drug substance goes into solution per unit of time under standardized conditions. The primary goal of dissolution testing is to be used as a qualitative tool to provide measurements of the bioavailability of a drug as well as to demonstrate bioequivalencefrom batch-to-batch. The bioavailability and bioequivalence data obtained as a result of dissolution testing can be used to guide the development of a new formulation and product development processes toward product optimization,as well as to ensure continuing product quality and performance of the manufacturing process. In addition,dissolution is a requirement for regulatory approval for product marketing and is a vital 232

Volume 2, Issue1, January 2011 component of the overall quality control program [38]. Computerized System Dissolution testing is conducted using a dissolution If the dissolution apparatus is computerized, the installation apparatus that conforms to the specifications outlined in qualification should document the manufacturers specifications the United States Pharmacopeia. There are seven types for the computer system and verify that the computer system in of dissolution apparatus; the apparatus chosen to place complies with manufacturers specifications. Documentation perform dissolution testing depends primarily on the should include model and serial number of associated hardware, drug dosage form. In order to have a high degree of operating system name and version, software name and version, assurance that the dissolution apparatus is consistent and location of master and back-up files, and CPU requirements such accurate in its performance,validation is required. as speed and hard drive capacity. Validation is defined as documented evidence that Environmental Conditions provides a high degree of assurance that a specific The installation qualification should document the environmental instrument performs according to manufacturers conditions that surround the dissolution apparatus conform to USP specifications and user requirements. Validation is standards, which require that no part of the assembly, including achieved by performing a series of validation activities; the environment in which the assembly is placed, contributes for a dissolution apparatus,validation is obtained through significant motion, agitation, or vibration beyond that due to the installation qualification and operational qualification. smoothly rotating stirring element. Installation Qualification Equipment Information Installation qualification consists of documented The installation qualification should document equipment verification that all key aspects of the dissolution information including the manufacturer, model number, and serial apparatus are in working condition and have been number of the dissolution apparatus, and verify that the information properly installed in accordance with manufacturers complies with purchase orders and user requirements. In addition, specifications in the proper operating environment. The verification of the units compliance with requirements outlined by installation qualification of a dissolution apparatus the USP <711> Dissolution General Chapter,and specific to each dissolution apparatus, should be performed. Requirements to be should include the following verifications: verified are summarized below .[39] Preventive maintenance The installation qualification should document that the Apparatus 1 dissolution apparatus is enrolled in a preventive Vessel: cylindrical, 160-210 mm high, inside diameter 98-106 maintenance program to assure that the system continues mm, nominal capacity is 1000 mL; sides are flanged at the top. to operate properly and no component part of the system Shaft: positioned so that its axis is not more than 2 mm at any point from the vertical axis of the vessel and rotates smoothly and becomes inoperable due to wear and use. without significant wobble. Calibration The installation qualification should document that Materials of Construction: Shaft and basket components are specific devices contained within the dissolution stainless steel, type 316 or equivalent. apparatus (e.g., speed, time, and temperature displays) Basket position: the distance between the inside bottom of the have been calibrated to traceable vessel and the basket is maintained at 25 +/- 2 mm during the test. standards.Documentation should include the date Apparatus 2 Vessel: cylindrical, 160-210 mm high, inside diameter 98-106 calibration was performed and when calibration is due. mm, nominal capacity is 1000 mL; sides are flanged at the top. SOPs The installation qualification should document that all Shaft: positioned so that its axis is not more than 2 mm at any SOPs pertaining to the dissolution apparatus are point from the vertical axis of the vessel and rotates smoothly and approved and in place. Applicable SOPs may include without significant wobble. preventive maintenance, calibration, operation, Materials of Construction: Shaft and blade are a single entity that may be coated with a suitable inert coating. document archival, and equipment logbook usage. Blade position: the distance between the inside bottom of the Utilities The installation qualification should document the vessel and the blade is maintained at 25 +/- 2 mm during the test. manufacturers specifications for required utilities and The blade passes through the diameter of the shaft so that the verify that the appropriate utilities are available for the bottom of the blade is flush with the bottom of the shaft. system. For example, utility verification may include Apparatus 3 confirming that the appropriate electrical power Reciprocating Cylinder: positioned so that during the upward and downward stroke, the reciprocating cylinder moves through a requirements (voltage, amperage, safety cut-offs) are documented and total distance of 9.9- 10.1 cm. Materials of Construction: Fittings are stainless steel, type 316 or comply with manufacturers specifications. equivalent. 233

Volume 2, Issue1, January 2011 considered successful if the percent of drug released at 30 minutes Apparatus 4 Materials of Construction: Flow-through cell, falls within a pre-established range. The ranges for each composed of transparent and inert material, is combination of apparatus and calibrators at 50 or 100 RPM are mounted vertically with a filter system that prevents established by the USP and are different for each lot of calibrators. escape of undissolved particles from the This test must be conducted for each of the vessels contained top of the cell. Tube connections are of polytef tubing within a dissolution apparatus. For a vessel to be acceptable, it with 1.6-mm diameter and chemically inert flanged-end must, individually, provide acceptable drug release from the connections. calibrator [40]. For sample aliquots withdrawn from the vessels, Cell Assembly: Cell diameters are 12 and 22.6 mm; the the solutions are analyzed using previously validated HPLC or apparatus uses a clamp mechanism and two O-rings for UV/Vis methods (depending on the monograph) that yield the fixation of the cell assembly. acceptable peak resolution and elution time. The analysis can then be used to create a profile of percent drug released vs. time. Apparatus 5 Vessel: cylindrical, 160-210 mm high, inside diameter Validation of Automated Versus Manual Procedures 98-106 mm, nominal capacity is 1000 mL; sides are At a minimum, the following verifications should be included in flanged at the top. the operational qualification of an automated dissolution system Shaft: positioned so that its axis is not more than 2 mm [41]: at any point from the vertical axis of the vessel and Software/hardware Communication rotates smoothly and without significant wobble. Verify that the software accurately controls the hardware. Materials of Construction: Shaft and blade are a single Operator Interface Functions entity that may be coated with a suitable inert coating. Verify that the system can be accurately controlled through Disk assembly is stainless steel. functions pre-defined by the manufacturer. For example, operator Blade Position: the distance between the surface of the interface testing may include confirming that all menu options are disk assembly and the blade is maintained at 25 +/- 2 available and that a file can be successfully created and modified. mm during the test. The disk assembly holds the system Stress/boundary/challenge Testing flat and is positioned such that the release surface is Verify that the system successfully performs under stress and/or parallel with the bottom of the paddle blade. challenge conditions that may be present during operation. For example, stress/boundary/ challenge testing may include Apparatus 6 Vessel: cylindrical, 160-210 mm high, inside diameter confirming that a maximum number of files can be processed 98-106 mm, nominal capacity is 1000 mL; sides are simultaneously, or that the system can perform simultaneous flanged at the top. functions. Shaft: positioned so that its axis is not more than 2 mm In addition, if the dissolution apparatus employs a computerized at any point from the vertical axis of the vessel and system, 21 CFR Part 11 requirements must be considered. At a rotates smoothly and without significant wobble. minimum, the following verifications should be included in the Materials of Construction: Cylinder stirring element is operational qualification: stainless steel, type 316 or equivalent. Report Printing/handling Cylinder Position: the distance between the inside Verify that all reports defined by the manufacturer are available bottom of the vessel and the cylinder is maintained at 25 and accurate. +/- 2 mm during the test. Audit Trail Verify that the audit trail accurately captures changes to the Operational Qualification Operational Qualification consists of documented system, including file creation, modification, deletion, and data evidence that the equipment operates as intended and is processing. capable of consistent operation within established Electronic Signatures specifications. The operational qualification of a Verify that electronic signatures are operational and accurate. dissolution apparatus should include the following Data archival and restoration verifications: Verify that data is successfully archived and restored. Data Integrity System Suitability (Calibration) A system suitability test using USP calibrators should be Verify that data integrity is not compromised during data backup, conducted during operational qualification testing. The archival, or restoration functions. procedure for dissolution and sampling is outlined in the System Security Certificates supplied with each USP Calibrator tablet for Verify that all applicable system security measures are each apparatus. The calibrators used for the test are operational (e.g., user name, password, screen saver, automatic disintegrating tablets (Prednisone) and non time-outs, user level definitions, etc.) disintegrating tablets (Salicylic Acid). The test is 234

Volume 2, Issue1, January 2011 Validation of Analytical Methods Employed in Preparation of a Buffer Solution Solutions called buffers are remarkably resistant to pH changes Quantitative Analysis of Dissolution Samples Analytical methods used to perform analysis of caused by the addition of an acid or base.These solutions always dissolution should be validated. Generally, this method contain both the salt of a weak acid or base, as well as the parent validation is not part of the operational qualification of acid or base. For example, a buffer solution containing a weak the dissolution apparatus. However, validated methods acid, HA, and the anion, A from its salt, will establish the should be employed to analyze the samples withdrawn following equilibrium: HA(aq) H+(aq) + A(aq) as part of the system suitability testing performed during the operational qualification.[42] and the [H+] can be calculated as follows: Temperature Distribution Study A temperature distribution study should be conducted [H+ ] = Ka [HA] during the operational qualification. The study should [A-] include temperature mapping of each vessel contained If a small amount of strong acid were added to that solution, the within the dissolution apparatus. Temperature should be H+ ion would tend to react with the A ion present, forming HA: mapped using a data acquisition system for a minimum H+ (aq) + A(aq) HA(aq) time that is based on the monograph or 1 Similarly, a small amount of strong base added to the solution will hour,whichever is greater. The temperature of Apparatus react with the HA present to form water and A ions: 1, 2, 3, and 4 must remain at 37C 0.5C; the HA(aq) + OH(aq) H2O(l) + A(aq) temperature of Apparatus 5 and 6 must remain at 32C In both cases, if the ratio [HA]/[A] changes only slightly, the 0.5C. [H+], and the pH, will remain approximately constant. If instead similar quantities of strong acid Rotation Speed Study A rotation speed study should be conducted during the or base are added to the same volume of water, the pH changes by operational qualification. The study should include a several units. measurement of the speed of the shaft rotation for each The objective of this experiment is to prepare a buffer solution and vessel contained within the dissolution apparatus. Speed to investigate the changes in pH that occur when known amounts should be measured using a photo tachometer for 30 of strong acid and strong base are added to it. These changes will minutes or the time specified in the individual be compared to the pH changes that occur in an identical volume monograph, whichever is greater. The speed of the shaft of water. rotation should be verified to be within 4% of the speed To prepare a buffer that would tend to have and maintain a given specified in the monograph.[43] pH value, a solution of a weak acid or base and a solution of the Buffer solutions are solutions which resist to changes in salt of that acid or base is needed. Given the value of Ka of the pH. Usually, buffer solutions acid, and the [H+] required in an acid buffer, the formula below consist of a weak acid and its conjugate base (for can be used to determine the [HA]/[A] ratio in the buffer. Ka = [H+ ] [A- ] example CH3COOH/CH3COO ) or a weak base and its conjugate acid (for example [HA] NH3/NH4+. A buffer solution is formed by partial neutralization of a By mixing appropriate volumes of the acid and salt solutions the weak acid with a strong base or of a weak base with a concentration ratio can easily be obtained and thus the buffer can strong acid. Alternatively, buffer solutions can be be made. Buffers will typically have H+ ion concentrations near the Ka values for the weak acid used: if the buffer is to be prepared by mixing the precalculated concentrations of each of the constituents. effective against the addition of both acid and base, the ratio The pH of a buffer solution, which is composed of a [A]/[HA] should be approximately one as indicated by the weak acid HA and its conjugate base Ais calculated by Henderson-Hasselbalch equation: pH = pK + log [A- ] the Henderson-Hasselbalch equation: pH= pKa + log [A- ] [ HA ]. Preparation of Buffer Solutions [HA] where Ka is the acid dissociation constant of the weak Dilute each of the mixtures to 1 L with distilled water. (NOTE: the pH will not be affected if the volumes are slightly more or less acid HA and [HA] and [A ] are the concentrations of HA and A in the buffer solution, than 1 L.) Important: The pH of each buffer must be checked and adjusted respectively. before being bottled. If the pH is too high, adjust the pH to the correct value by adding 235

Volume 2, Issue1, January 2011 1 M HCl, with stirring. Alkali / Basic Buffer If the pH is too low, adjust the pH to the correct value Composition by adding 1 M NaOH, with stirring A basic buffer is composed of a weak base (B) and its conjugate pH Mixture acid (BH+) / weak base and the salt of the weak base and a strong acid. 3 10.21 g of potassium hydrogen phthalate + 223 mL of 0.10 M HCl How to make a basic buffer 4 10.21 g of potassium hydrogen phthalate + 1 mL of 0.10 M HCl 1) Start with a weak base and strong acid of the same 5 10.21 g of potassium hydrogen phthalate + 226 mL concentration (e.g. 0.10 moldm3). of 0.10 M NaOH Take about 25cm3 of a strong acid and add an excess of weak 6 6.81 g of potassium phosphate monobasic + 56 mL of base (about 50 cm3) so that 0.10 M NaOH there are sufficient moles of the weak base to neutralize all of the 7 6.81 g of potassium phosphate monobasic + 291 mL strong acid, leaving of 0.10 M NaOH excess base in the solution. 8 6.81 g of potassium phosphate monobasic + 467 mL of 0.10 M NaOH OH (aq) + H+(aq) A(aq) + OH(aq) 9 4.77 g of sodium tetraborate + 46 mL of 0.10 M HCl excess limiting salt excess weak base 10 4.77 g of sodium tetraborate + 183 mL of 0.10 M NaOH 11 2.10 g of sodium bicarbonate + 227 mL of 0.10 M buffer solution in the buffer the [OH ] = [ A ] NaOH OR Composition of Buffer Solutions 2) Add equal concentration and volume (equal moles) of a weak In normal water (nonbuffered solution) if you add a base and the salt of the weak base and a strong acid.(38) small amount of a strong acid or base, it will cause the Buffer Solutions pH of the water to change significantly. Two drops of 1 A. Standard Buffer Solutions mol dm3 HCl added to water will change the pH from 7 Standard Buffer Solutions are solutions of standard pH. They are to 4. used for reference purposes in pH measurements and for carrying Acidic buffers out many pharmacopoeial tests which require adjustments to or Composition maintenance of a specified pH. They may be prepared by the An acidic buffer is composed of a weak acid (HA) and methods described below. The preparation of special buffer its conjugate base (A) or a weak acid and the salt of the solutions is described in the sections in which their use is specified weak acid and a strong base. as in the microbiological assay of antibiotics or in the individual How to make an acidic buffer monographs where the use of such solutions is indicated. The 1) Start with a weak acid and strong base of the same reagents required for the preparation of standard buffer solutions concentration (e.g. 0.10 moldm3). are described in Appendix 4.2. All the crystalline reagents except Take about 25cm3 of a strong base and add an excess boric acid should be dried at 110 to 120 for 1 hour before use. moles of a weak acid (50cm3) so that Carbon dioxide-free water should be used for preparing buffer there is a sufficient number of moles of the weak acid to solutions and wherever water is mentioned for preparation of such completely neutralize all the moles of strong base solutions the use of carbon dioxide-free water is implied. The .Excess weak acid is added so that the resulting solution prepared solutions should be stored in chemically resistant, glasscontains the salt (conjugate base), water and excess stoppered bottles of alkakli-free glass and used within 3 months of weak acid. preparation. Any solution which has become cloudy or shows any other evidence of deterioration should be discarded. Standard OH (aq) + H+(aq) A(aq) + H+(aq) buffer solutions for various ranges of pH values 1.2 to 10.0 may Limiting excess salt excess weak acid be prepared by appropriate combinations of 0.2 M hydrochloric acid or 0.2 M sodium hydroxide and of solutions described below, used in the proportions shown in the accompanying tables. The buffer solution in the buffer the standard pH values given in the tables and elsewhere in the [HA ] = [ A ] Appendix are considered to be reproducible within 0.02 Unit at Or 2) Add equal concentration and volume (equal moles) of 25. a weak acid (HA) and the salt of the weak acid and a 1. Boric Acid and Potassium Chloride, 0.2 M: Dissolve 12.366 g of boric acid and 14.911 g of potassium chloride in water and strong base (A). 236

Volume 2, Issue1, January 2011 dilute with water to 1000 ml. TABLE 2. 2. Disodium Hydrogen Phsophate, 0.2 M: Dissolve PH 0.2 M HCL , ml 71.630 g of disodium hydrogen phosphate in water and SNO. dilute with water to 1000 ml. 1 2.2 49.5 3. Hydrochloric Acid, 0.2 M: Hydrochloric acid diluted 2 2.4 42.2 with water to contain 7.292 g of HCl in 1000 ml. 3 2.6 35.4 Standardise as directed in Appendix 4.4. 4 2.8 28.9 4. Potassium Chloride, 0.2 M: Dissolve 14.911 g of 5 3.0 22.3 potassium chloride in water and dilute with water to 6 3.2 15.7 1000 ml. 7 3.4 10.4 5. Potassium Dihydrogen Phosphate, 0.2 M: Dissolve 8 3.6 6.3 27.218 g of potassium dihydrogen phosphate in water 9 3.8 2.9 and dilute with water to 1000 ml. 10 4.0 0.1 6. Potassium Hydrogen Phthalate, 0.2 M: Dissolve Neutralised Phthalate Buffer; Phthalate Buffer: Place 50.0 ml 40.846 g of potassium hydrogen phthalate in water and of 0.2 M potassium hydrogen phthalate in a 200-ml volumetric dilute with water to 1000 ml. flask, add the specified volume of 0.2 M sodium 7. Sodium Hydroxide, 0.2 M: Dissolve sodium hydroxide (see Table 3) and then add water to volume. hydroxide in water to produce a 40 to 60 per cent w/v TABLE:-3 solution and allow to stand. Taking precautions to avoid SNO. PH 0.2M NaOH, ml absorption of carbon dioxide, siphon off the clear 1 4.2 3.0 supernatant liquid and dilute with carbon dioxide-free 2 4.4 6.6 water a suitable volume of the liquid to contain 8.0 g of 3 4.6 11.1 NaOH in 1000 ml. Standardise as directed in 4 4.8 16.5 Appendix 4.4. 5 5.0 22.6 Composition of Standard Buffer Solutions 6 5.2 28.8 Hydrochloric Acid Buffer: Place 50.0 ml of the 0.2 M 7 5.4 34.1 potassium chloride in a 200-ml volumetric flask, add the 8 5.6 38.1 specified volume of 0.2 M hydrochloric acid (see Table 9 5.8 42.3 1) and then add water to volume. TABLE 1. Phosphate Buffer: Place 50.0 ml of 0.2 M potassium dihydrogen SNO. PH 0.2 M HCL , ml phosphate in a 200-ml volumetric flask, add the specified volume of 0.2 M sodium hydroxide and then add water to volume.( 1 1.2 85.0 TABLE 4 2 1.3 67.2 SNO. PH 0.2M NaOH, ml 3 1.4 53.2 1 5.8 3.6 4 1.5 41.4 2 6.0 5.6 5 1.6 32.4 3 6.2 8.1 6 1.7 26.0 4 6.4 11.6 7 1.8 20.4 5 6.6 16.4 6 6.8 22.4 8 1.9 16.2 7 7.0 29.1 9 2.0 13.0 8 7.2 34.7 10 2.1 10.2 9 7.4 39.1 11 2.2 7.8 10 7.6 42.4 11 7.8 44.5 Acid Phthalate Buffer: Place 50.0 ml of 0.2 M 12 8.0 46.1 potassium hydrogen phthalate in a 200-ml volumetric flask, add the specified volume of 0.2 M hydrochloric Alkaline Borate Buffer: Place 50.0 ml of 0.2 M boric acid and acid (see Table 2) and then add water to volume. potassium chloride in a 200-ml volumetric flask, add the specified volume of 0.2 M sodium hydroxide (see Table 5) and then add water to volume. 237

Volume 2, Issue1, January 2011 to produce 1000 ml. Adjust the pH, if necessary. Acetate Buffer pH 6.0: Dissolve 100 g of ammonium acetate in 300 ml of water, add 4.1 ml of glacial acetic acid, adjust the pH, if SNO. PH 0.2M NaOH, ml necessary, using 10 M ammonia or 5 M acetic acid and dilute with 1 8.0 3.9 water to 500 ml. 2 8.2 6.0 Acetate Buffer Solution: Dissolve 14 g of potassium acetate and 3 8.4 8.6 20.5 ml of glacial acetic acid in sufficient water to produce 1000 4 8.6 11.8 ml. 5 8.8 15.8 Acetic Acid-Ammonium Acetate Buffer: Dissolve 77.1 g of 6 9.0 20.8 ammonium acetate in water, add 57 ml of glacial acetic acid and 7 9.2 26.4 dilute with water to 1000 ml. 8 9.4 32.1 Acetic Ammonia Buffer pH 3.7, Ethanolic: To 15 ml of 5 M 9 9.6 36.9 acetic acid add 60 ml of ethanol (95 per cent) and 24 ml of water. 10 9.8 40.6 Adjust the pH to 3.7 with 10 M ammonia and dilute 11 10.0 43.7 with water to 100 ml. Other Buffer solutions Acetone Solution, Buffered: Dissolve 8.15 g of sodium acetate Acetate Buffer pH 2.8: Dissolve 4 g of anhydrous and 42 g of sodium chloride in water, add 68 ml of 0.1 M sodium acetate in about 840 ml of water, add sufficient hydrochloric acid and 150 ml of acetone and dilute with water glacial acetic acid to adjust the pH to 2.8 (about 155 ml) to 500 ml. and dilute with water to 1000 ml. Albumin Phosphate Buffer pH 7.2; Phosphate-albumin Acetate Buffer pH 3.4: Mix 50 ml of 0.1 M sodium Buffered Saline pH 7.2: Dissolve 10.75 g of disodium hydrogen acetate with 950 ml of 0.1 M acetic acid. phosphate, 7.6 g of sodium chloride and 10 g of bovine albumin in Acetate Buffer pH 3.5: Dissolve 25 g of ammonium sufficient water to produce 1000 ml. Before use adjust to pH 7.2 acetate in 25 ml of water and add 38 ml of 7 M with 2M sodium hydroxide or a 10 per cent w/v solution of hydrochloric acid. Adjust the pH to 3.5 with either 2 M phosphoric acid as required. hydrochloric acid or 6 M Ammonia-Ammonium Chloride Buffer: Dissolve 67.5 g of ammonia and dilute with water to 100 ml. ammonium chloride in about 200 ml of water, add 570 ml of Acetate Buffer pH 3.7: Dissolve 10 g of anhydrous strong ammonia solution and dilute with water to 1000 ml. sodium acetate in 300 ml of water, adjust to pH to 3.7 Ammonia Buffer pH 9.5: Dissolve 33.5 g of ammonium chloride with glacial acetic acid and dilute with water to 1000 ml. in 150 ml of water, and 42 ml of 10 M ammonia and dilute with Before use adjust to pH 3.7, if necessary, with glacial water to 250 ml. Store in polyethylene containers. acetic acid or anhydrous sodium acetate, as required. Ammonia Buffer pH 10.0: Dissolve 5.4 g of ammonium chloride Acetate Buffer pH 4.0: Place 2.86 ml of glacial acetic in 20 ml of water, add 35 ml of 10 M ammonia and dilute with acid and 1.0 ml of a 50 per cent w/v solution of sodium water to 100 ml. hydroxide in a 1000-ml volumetric flask, add water to Ammonia Buffer pH 10.9: Dissolve 67.5 g of ammonium volume and mix. Adjust the pH, if necessary. chloride in sufficient 10 M ammonia to produce 1000 ml. Acetate Buffer pH 4.4: Dissolve 136 g of sodium Barbitone Buffer pH 7.4: Mix 50 ml of solution containing 1.944 acetate and 77 g of ammonium acetate in water and per cent w/v of sodium acetate and 2.946 per cent w/v of barbitone dilute with water to 1000 ml. Add 250 ml of glacial sodium with 50.5 ml of 0.1 M hydrochloric acid, acetic acid and mix. add 20 ml of an 8.5 per cent w/v solution of sodium chloride and Acetate Buffer pH 4.6: Dissolve 5.4 g of sodium dilute with water to 250 ml. acetate in 50 ml of water, add 2.4 ml of glacial acetic Barbitone Buffer pH 8.6, Mixed; Barbitone Buffer pH 8.6: acid and dilute with water to 100 ml. Adjust the pH, if Dissolve 1.38 g of barbitone, 8.76 g of barbitone sodium and 0.38 necessary. g of calcium lactate in sufficient water to produce 1000 ml. Acetate Buffer pH 4.7: Dissolve 8.4 g of sodium Boric Buffer pH 9.0; Borate Buffer pH 9.0: Dissolve 6.20 g of acetate and 3.35 ml of glacial acetic acid in sufficient boric acid in 500 ml of water, adjust to pH 9.0 with 1 M sodium water to produce 1000 ml. Adjust the pH, if necessary. hydroxide (about 41.5 ml) and dilute with water to 1000 ml. Acetate Buffer pH 5.0: Dissolve 13.6 g of sodium Buffer Solution pH 2.5: To 25.0 ml of 0.2 M potassium hydrogen acetate and 6 ml of glacial acetic acid in sufficient water phthalate add 37.0 ml of 0.1 M hydrochloric acid and dilute with to produce 1000 ml. Adjust the pH, if necessary. sufficient water to produce 100.0 ml. Acetate Buffer pH 5.5: Dissolve 272 g of sodium Buffer (HEPES) solution pH 7.5: Dissolve 2.38 g of 2[4acetate in500 ml of water by heating to 35, cool and add (hydroxyethyl)piperazin-1-yl]ethanesulphonic acid in about 90 ml slowly 50 ml of glacial acetic acid and sufficient water of water. Adjust the pH to 7.5 with sodium hydroxide TABLE 5. 238

Volume 2, Issue1, January 2011 solution. Dilute to 100 ml with water. water. Dilute with water to 500 ml and stir until solution is Carbonate Buffer pH 9.7: Dissolve 8.4 g of sodium complete. bicarbonate and 10.6 g of sodium carbonate in sufficient Imidazole Buffer pH 6.5: Dissolve 6.81 g of imidazole and 1.23 water to produce 500 ml. g of magnesium sulphate in 752 ml of 0.1 M hydrochloric acid, Chloride Buffer pH 2.0: Dissolve 6.57 g of potassium adjust the pH if necessary and dilute with water to produce 1000 chloride in water, add 119.0 ml of 0.1 M hydrochloric ml. acid and dilute with water to 1000 ml. Imidazole Buffer pH 7.4: Dissolve 3.40 g of imidazole and 5.84 Citro-phosphate Buffer pH 5.0: Mix 48.5 ml of 0.1 M g of sodium chloride in water, and 18.6 ml of 1 M hydrochloric citric acid with sufficient 0.2 M disodium hydrogen acid and dilute with water to produce 1000 ml. phosphate to produce 100 ml. Palladium Chloride Solution, Buffered: To 0.5 g of palladium Citro-phosphate Buffer pH 6.0: Mix 36.8 ml of a 2.1 chloride add 5 ml of hydrochloric acid and warm on a waterbath. per cent w/v solution of citric acid with 63.2 ml of a Add 200 ml of hot water in small portions with continued heating 7.15 per cent w/v solution of disodium hydrogen until solution is complete. Cool and dilute with sufficient water to phosphate. produce 250.0 ml. To 50.0 ml of the resulting solution add 10.0 ml Citro-phosphate Buffer pH 7.0: Mix 17.6 ml of a 2.1 of 1 M sodium acetate, 9.6 ml of 1 M hydrochloric acid and per cent w/v solution of citric acid with 82.4 ml of a sufficient water to produce 100.0 ml. 7.15 per cent w/v solution of disodium hydrogen Phosphate-albumin buffered saline pH 7.2: Dissolve 10.75 g of phosphate. disodium hydrogen phosphate, 7.6 g of sodium chloride and 10 g Citro-phosphate Buffer pH 7.2: Mix 13.0 ml of a 2.1 of bovin albumin in water and dilute to 1000.0 ml with the same per cent w/v solution of citric acid with 87.0 ml of a solvent. Immediately before use adjust the Ph (2.4.24 )using dilute 7.15 per cent w/v solution of disodium hydrogen sodium hydrogen solution or dilute phosphoric acid. phosphate. Phosphate Buffer pH 2.0: Dissolve 0.136 g of potassium Citro-phosphate Buffer pH 7.6: Dissolve 1.33 g of dihydrogen phosphate in 800 ml of water, adjust the pH to 2.0 citric acid and 67.1 g of disodium hydrogen phosphate with hydrochloric acid and add sufficient water to produce 1000 in sufficient water to produce 1000 ml. ml. Cupric Sulphate Solution pH 2.0, Buffered: Mix 5.3 Phosphate Buffer pH 2.5: Dissolve 100 g of potassium ml of 0.2 M hydrochloric acid and 25 ml of 0.2 M dihydrogen phosphate in 800 ml of water, adjust the pH to 2.5 potassium chloride, add 4 ml of a 0.393 per cent w/v with hydrochloric acid and add sufficient water to produce solution of cupric sulphate and dilute to 100 ml of water. 1000 ml. Cupric Sulphate Solution pH 4.0, Buffered: Dissolve Phosphate Buffer pH 3.6: Dissolve 0.900 g of anhydrous 0.25 g cupric sulphate and 4.5 g of ammonium acetate in disodium hydrogen phosphate and 1.298 g of citric acid sufficient water to produce 100 ml. monohydrate in sufficient water to produce 1000 ml. Cupric Sulphate Solution pH 5.2, Buffered: Dissolve Phosphate Buffer pH 4.0, Mixed: Dissolve 5.04 g disodium 1.522 g of anhydrous disodium hydrogen phosphate in hydrogen phosphate and 3.01 g of potassium dihydrogen sufficient water to produce 53.6 ml and add a 2.1 per phosphate in sufficient water to produce 1000 ml. Adjust the pH cent solution of with glacial acetic acid. citric acid until the pH of the solution is between 5.15 Phosphate Buffer pH 4.9: Dissolve 40 g of sodium dihydrogen and 5.25 (about 46 ml). Mix 98.5 ml of the resulting phosphate and 1.2 g of sodium hydroxide in sufficient water to solution with 1.5 ml of a 0.393 per cent solution of produce 100 ml. If necessary, adjust the pH with 1 M cupric sulphate. sulphuric acid or 1 M sodium hydroxide as required. Diethanolamine Buffer pH 10.0: Dissolve 96.4 g of Phosphate Buffer pH 5.0: Dissolve 6.8 g of potassium diethanolamine in sufficient water to produce 400 ml. dihydrogen phosphate in 1000 ml of water and adjust the pH to Add 0.5 ml of an 18.6 per cent w/v solution of 5.0 with 10 M potassium hydroxide. magnesium chloride, adjust the pH to 10.0.with 1 M Phsophate Buffer pH 5.5, Mixed hydrochloric acid and dilute with water to 500 ml. SOLUTION I Dissolve 13.61 g of potassium dihydrogen Glycine Buffer pH 11.3: Mix a solution containing 0.75 phosphate in sufficient water to produce 1000 ml. per cent w/v of glycine and 0.58 per cent w/v of sodium SOLUTION II Dissolve 35.81 g of disodium hydrogen chloride with an equal volume of 0.1 M sodium phosphate in sufficient water to produce 1000 ml. hydroxide. Adjust the pH if necessary. Mix 96.4 ml of solution I with 3.6 ml of solution II. Glycine Buffer Solution: Mix 42 g of sodium Phosphate Buffer pH 6.5: Dissolve 60.5 g of disodium hydrogen bicarbonate and 50 g of potassium bicarbonate with 180 phosphate and 46 g of potassium dihydrogen phosphate in water, ml of water and add a solution containing 37.5 g of add 100 ml of 0.02 M disodium edentate and 20 mg of mercuric glycine and 15 ml of strong ammonia in 180 ml of chloride and dilute with water to produce 1000 ml. 239

Volume 2, Issue1, January 2011 Phosphate Buffer pH 6.8, Mixed: Dissolve 28.80 g of sufficient water to produce 1000 ml. Adjust the pH if necessary. disodium hydrogen phosphate and 11.45 g of potassium Tris-acetate buffer solution pH 8.5: Dissolve 0.294 g of calcium dihydrogen phosphate in sufficient water to produce chloride of tris(hydroxymethyl)aminomethane in water. Adjust the 1000 ml. pH(2.4.24) with acetic acid. Dilute to 1000.0 ml with water. Phosphate Buffer pH 6.8, 0.2 M Mixed: Dissolve Tris(hydroxymethyl)aminomethane buffer solution pH 7.4: 13.872 g of potassium dihydrogen phosphate and 35.084 Dissolve 30.3 g of tris(hydroxymethyl)aminimethane in g of disodium hydrogen phosphate in sufficient water to approximately 200 ml of water. Add 183 ml of 1 M hydrochloric produce 1000 ml. Store in a cold place. acid. Dilute to 500.0 ml with water.[45] Phosphate Buffer pH 7.0, Mixed: Dissolve 0.50 g of NOTE The pH is 7.7-7.8 at room temperature and 7.4 at 37. anhydrous disodium hydrogen phosphate 0.301 g of This solution is stable for several months at 4. potassium dihydrogen phosphate in sufficient water to Conclusion:- In this above study we get familiar with the different produce 1000 ml. dissolution apparatus the buffers which are used in it and we now Phosphate Buffer pH 7.0 with Azide, Mixed: To 1000 know that how dissolution is very much necessary and how we ml of a solution containing 1.8 per cent w/v of disodium have to make the different types of buffers. hydrogen phosphate and 2.3 per cent w/v of sodium chloride, add sufficient of a solution containing 0.78 per cent w/v of sodium dihydrogen phosphate and 2.3 per References:cent w/v of sodium chloride (about 280 ml) to produce a 1. Dissolution <711>. In United States Pharmacopeia and pH of 7.0. Dissolve sufficient sodium azide in the National Formulary USP 31NF 26; The United States resulting solution to give a 0.02 per cent w/v solution. Pharmacopeial Convention, Inc.: Rockville, MD, 2007. Phosphate Buffer pH 7.0, 0.067 M Mixed: Dissolve 2. Dissolution test for solid dosage forms. In European 3.532 g of potassium dihydrogen phosphate and 14.542 Pharmacopoeia, 5th ed.; European Directorate for the Quality g of disodium hydrogen phosphate in sufficient water to of Medicines, Council of Europe: Strasbourg, France, 2005. produce 1000 ml. 3. Dissolution Test. In Japanese Pharmacopoeia, 15th ed.; Phsophate Buffer pH 7.5, 0.33 M Mixed Ministry of Health, Labour, and Welfare: Tokyo, Japan, 2007. SOLUTION I Dissolve 119.31 g of disodium 4. Kukura, J.; Baxter, J. L.; Muzzio, F. J. Shear distribution and hydrogen phosphate in sufficient water to produce 1000 variability in the USP apparatus 2 under turbulent conditions. ml. Int. J. Pharm. 2004, 279, 917. SOLUTION II Dissolve 45.36 g of potassium 5. Healy, A. M..; McCarty, L. G.; Gallagher, K. M.; Corrigan, G. dihydrogen phosphate in sufficient water to produce I. Sensitivity of dissolution rate to location in the paddle 1000 ml. dissolution apparatus. J. Pharm. Pharmacol. 2002, 54, 441 Mix 85 ml of solution I and 15 ml of solution II and 444. adjust the pH if necessary. 6. Mirza, T.; Joshi, Y.; Liu, G.; Vivilecchia, R. Evaluation of Phosphate Buffer pH 8.0, 0.02 M: Mix 50 ml of 0.2 M Dissolution Hydrodynamics in the USP, Peak and Flatpotassium dihydrogen phosphate with 46.8 ml of 0.2 M Bottom Vessels Using Different Solubility Drugs. Dissolution sodium hydroxide and add sufficient water to produce Technol. 2005, 12 (1), 1116. 500 ml. 7. Gray, V. Identifying sources of error in calibration and sample Phosphate Buffer, 0.025 M Standard: Dissolve 3.40 g testing. Am. Pharm. Rev. 2002, 5 (2), 813. of potassium dihydrogen phosphate and 3.55 g of 8. USP Informational General Chapter <1092> The Dissolution anhydrous disodium hydrogen phosphate, both Procedure: Development and Validation. Pharm. Forum 2005, previously dried at 110 to 130 for 2 hours, in sufficient 31, 14631475. water to produce 1000 ml. 9. Hanson, R; Gray V. Handbook of Dissolution Testing, 3rd ed.; Saline, Phosphate-buffered: Dissolve 2.5 g of sodium Dissolution Technologies, Inc.: Hockessin, DE, 2004. dihydrogen phosphate, 2.523 g of disodium hydrogen 10. Dressman, J.; Kramer, J. Pharmaceutical Dissolution Testing; phosphate and 8.2 g of sodium chloride in sufficient Taylor and Francis: Boca Raton, FL, 2005. water to produce 1000 ml. 11. Phrma Dissolution Calibration Subcommittee. Dissolution Saline pH 6.4, Phosphate-buffered: Dissolve 1.79 g of Calibration: Recommendations for Reduced Chemical Testing disodium hydrogen phosphate, 1.36 g of potassium and Enhanced Mechanical Calibration. Pharm. Forum 2000, dihydrogen phosphate and 7.02 g of sodium chloride in 26, 11491166. sufficient water to produce 1000 ml. 12. Beyer, W.; Smith, D. Unexpected variable in the USP/NF Saline pH 7.4, Phosphate-buffered: Dissolve 2.38 g of rotating basket dissolution rate test. J. Pharm. Sci. 1971, 60, disodium hydrogen phosphate, 0.19 g of potassium 23502351. dihydrogen phosphate and 8.0 g of sodium chloride in 240

Volume 2, Issue1, January 2011 Tool in the Early Development Stage? Experiences with Immediate13. Hanson, W. Solving the puzzle of random variables in Release Dosage Forms. Dissolution Technol. 2006, 13 (4), 611. dissolution testing. Pharm. Tech. 1977, 1, 3041. 14. Collins, C. C. Vibration: What Is It and How Does It 28. Testing and release for distribution. Current Good Manufacturing Practice for Finished Pharmaceuticals, Code of Federal Affect Dissolution Testing? Dissolution Technol. Regulations, Title 21, Vol. 4, Part 211.165(e), 2008. 1998, 5 (4), 1618. 15. Thakker, K.; Naik, N.; Gray, V.; Sun, S. Fine tuning of 29. Scale-Up and Postapproval Changes for Modified Release Solid Oral Dosage Forms; Guidance for Industry; U.S. Department of the dissolution apparatus. Pharm. Forum 1980, 6, 177 Health and Human Services, Food and Drug Administration, 185. Center for Drug Evaluation and Research (CDER), U.S. 16. Crist, B.; Spisak, D. Evaluation of Induced Variance of Government Printing Office: Washington, DC, 1997. Physical Parameters on the Calibrated USP Dissolution Apparatus 1 and 2. Dissolution Technol. 2005, 12 (1), 30. Mehta, M. FDA Expectations. Consortium on Drug Eluting Stents; Office of Pharmaceutical Science, Food and Drug 2834. Administration, Center for Drug Evaluation and Research 17. Scott, P. Geometric Irregularities Common to the (CDER); March 25, 2003. Dissolution Vessel. Dissolution Technol. 2005, 12 (1), 31. Indian pharmacopeia 2007 [2.5.1] Dissolution test page no 180. 1821. 32. Indian pharmacopeia 2007[2.5.2]Dissolution test page no 189. 18. Cox, D. C.; Wells, C. E.; Furman, W. B.; Savage, T. 33. .Indian pharmacopeia 2007 [2.5.3]. Uniformity weight of single S.; King, A. C. Systematic error associated with dose preparations.page no. (187-190) apparatus 2 of the USP dissolution test II: effect of 34. Shah, V. P., et al., 1989, "In Vitro Dissolution Profile of Water deviations in vessel curvature from that of a sphere. J. Insoluble Drug Dosage Forms in the Presence of Surfactants," Pharm. Sci. 1982, 71, 395399. Pharmaceutical Research, 6:612-618. 19. Tanaka, M.; Fujiwara, H.; Fujiwara, M. Effect of the 35. Shah, V. P., et al., 1995, "In Vivo Dissolution of Sparingly Water Irregular Inner Shape of a Glass Vessel on Prednisone Soluble Drug Dosage Forms," International Journal of Dissolution Results. Dissolution Technol. 2005, 12 (4), Pharmaceutics, 125:99-106. 1519. 20. Baxter, J. L.; Kukura. J.; Muzzio, F. J. 36. Dissolution <711>. In United States Pharmacopeia and National Formulary USP 31NF 26; The United States Pharmacopeial Hydrodynamicsinduced variability in the USP Convention, Inc.: Rockville, MD, 2008. apparatus II dissolution test. Int. J. Pharm. 2005, 292, 37. Drug Release <724>. In United States Pharmacopeia and 1728. National Formulary USP 31NF 26; The United States 21. Vangani, S.; Flick, T.; Tamayo, G.; Chiu, R.; Cauchon, Pharmacopeial Convention, Inc.: Rockville, MD, 2008; Vol. 1. N. Vibration Measurements on Dissolution Systems and Effects on Dissolution of Prednisone Tablets RS. 38. Ansel,Howard C., Lloyd V. Allen, Jr., and Nicholas G. Popovich. Pharmaceutical Dosage Forms and Drug Delivery Systems. Dissolution Technol. 2007, 14 (1), 614. Baltimore,Maryland: Lippincott Williams & Wilkins, 7th edition, 22. Eaton, J.; Deng, G.; Hauck, W.; Brown, W. E. W.; 1999. Manning, R. G.; Wahab, S. Z. Perturbation Study of Dissolution Apparatus VariablesA Design of 39. United States Pharmacopeial Convention, Inc. United States Pharmacopeia 26. Rockville,Maryland: United States Experiment Approach. Dissolution Technol. 2007, 14 Pharmacopeial Convention, Inc. 2003. (1), 2027. 23. Liddell, M.; Deng, G.; Hauck, W. W.; Brown, W. E.; 40. Qureshi, S.A. The USP Dissolution Apparatus Suitability Test. Drug Information Journal. 1996; 30; 1055-1061. Wahab, S. Z.; Manning, R. G. Evaluation of Glass Dissolution Vessel Dimensions and Irregularities. 41. GAMP Guide Forum. GAMP 4. GAMP Guide Forum and ISPE. 2003. Dissolution Technol. 2007, 14 (1), 2834. 24. Indian pharmacopeia 2007.Dissolution test page 42. Food and Drug Administration. Guidance for Industry, Dissolution Testing of Immediate Release Solid Oral Dosage no.179-180 Forms. Rockville,Maryland: Food and Drug Administration, 25. Palmieri, A., Ed. Dissolution Theory, Methodology, Center for Drug Evaluation and Research. 1997. and Testing; Dissolution Technologies, Inc.: 43. Sharon M.Averell Frost, Senior Technical Services Hockessin, DE, 2007. Scientist,Technical Services Dept., Wyeth Vaccines, 4300 Oak 26. Dissolution <711>. In United States Pharmacopeia and Park, Sanford, NC,27330,Dissolution technologies,Febuary 2004. National Formulary USP 31NF 26; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2008. 44. .Mauro Di Renzo & Vanier College Chemistry Department revised 2008. 27. Klein, S. The Mini Paddle Apparatusa Useful 45. Indian pharmacopeia 2007 (4.1). Buffer solutions .page no 245.

241